Nom du produit:4-bromo-6-hydroxypyrazolo[1,5-a]pyridine-3-carbonitrile

IUPAC Name:4-bromo-6-hydroxypyrazolo[1,5-a]pyridine-3-carbonitrile

CAS:2068065-05-2
Formule moléculaire:C8H4BrN3O
Pureté:95%+
Numéro de catalogue:CM325559
Poids moléculaire:238.04

Unité d'emballage Stock disponible Prix($) Quantité
CM325559-100mg in stock ȡǑ
CM325559-250mg in stock Ǒȡƛ
CM325559-1g in stock ƛȡǶ

Pour une utilisation en R&D uniquement..

Formulaire de demande

   refresh    

Détails du produit

N° CAS:2068065-05-2
Formule moléculaire:C8H4BrN3O
Point de fusion:-
Code SMILES:N#CC1=C2C(Br)=CC(O)=CN2N=C1
Densité:
Numéro de catalogue:CM325559
Poids moléculaire:238.04
Point d'ébullition:
N° Mdl:
Stockage:

Category Infos

Pyrazolopyridines
Over the past few years, many pyrazole fused-ring systems, especially with applications in medicinal chemistry, have been published. These include general structures such as pyrazoline, pyrazoline, pyrazoquinoline, pyrazoloisoquinoline, pyrazoline, pyrazolopyrazine, pyrazolopyrazine, pyranopyrazole, pyrano Pyrazoles, pyrazolotriazines and pyrazole fused phosphorus rings.

Column Infos

Selpercatinib
The FDA has granted accelerated approval to selpercatinib (Retevmo; Eli Lilly and Company) for pediatric patients aged 2 years and older with RET-altered metastatic thyroid cancer or solid tumors, the federal agency announced in a press release. Selpercatinib is a highly selective, potent RET inhibitor. It works by blocking a type of enzyme (kinase) and helps prevent the cancer cells from growing.

Related Products